DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
RapidMLAMSRAGP

Cutaneous squamous-cell carcinoma

Essential points for quick revision.

Synopsis

Recognise invasive cutaneous squamous-cell carcinoma, identify clinical and pathological high-risk features, refer every suspected lesion urgently and coordinate excision, nodal assessment and prevention.

  • Suspect SCC in a persistent enlarging tender indurated keratotic, crusted or ulcerated lesion, particularly on chronically sun-exposed skin.
  • NICE recommends urgent suspected-cancer referral for every lesion clinically suspicious for cutaneous SCC.
  • High-risk features include lip or ear site, diameter over 2 cm, depth over 6 mm or beyond subcutaneous fat, poor differentiation, perineural invasion, recurrence and immune suppression.

Key red flags

Rapid growth, severe pain, numbness, fixation, recurrent tumour, lip or ear site, diameter over 2 cm, immune suppression, palpable nodes or chronic-scar ulceration requires urgent suspected-cancer referral and high-risk staging.

Lip or ear tumour

Persistent keratotic ulceration on vermilion lip or pinna carries higher metastatic risk and demands urgent referral.

Investigation priorities

01
Deep representative biopsyFirst step

Confirm SCC and measure invasive and pathological risk features.

Management branches

Suspected SCCRefer every invasive suspicion urgently

A persistent indurated keratotic, ulcerated or rapidly growing lesion could represent invasive SCC.

  1. Measure and document morphology, growth, site, immune status, neurological symptoms and regional nodes.
  2. Make an urgent suspected-cancer referral, leaving the lesion available for appropriately deep biopsy and definitive planning.
Open full textbook Answer 2 questions
Sources and review status3 sources · checked 27 Aug 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom